iTabMed

天劢源和

iTabMed

Biotech/Healthcare

Tianmai Yuanhe is a developer of innovative oncology immunotherapy drugs, focused on developing an immunotherapy antibody technology platform. Through immunotherapy that activates the human immune system to continuously kill and clear cancer cells, it aims to deliver clinical efficacy for cancer…

Latest round: Series A (2021)

Source: ChinaBulls — chinabulls.com

Last updated 2021-12-01